Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia

BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Epidemiol
Auteurs principaux: Hagberg, Katrina Wilcox, Divan, Hozefa A, Fang, Shona C, Nickel, J Curtis, Jick, Susan S
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2017
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312705/
https://ncbi.nlm.nih.gov/pubmed/28228662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S124674
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires